Open AccessEffects of topiramate on the association between affect, cannabis craving, and cannabis use in the daily life of youth during a randomized clinical trial
Author(s) -
Noah N. Emery,
Ryan W. Carpenter,
Samuel N. Meisel,
Robert Miranda
Publication year - 2021
Publication title -
psychopharmacology/psychopharmacologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.378
H-Index - 196
eISSN - 1432-2072
pISSN - 0033-3158
DOI - 10.1007/s00213-021-05925-5
Subject(s) - topiramate , craving , affect (linguistics) , cannabis , psychology , placebo , randomized controlled trial , mood , psychiatry , alcohol use disorder , clinical psychology , medicine , addiction , alcohol , chemistry , alternative medicine , communication , pathology , epilepsy , biochemistry
Topiramate is an anticonvulsant currently under study for treating substance use disorders. Topiramate is thought to reduce substance use by attenuating craving and the rewarding effects of acute substance use through its concurrent GABAergic agonism and glutamatergic antagonism. Importantly, topiramate also impacts mood states central to many models of substance use. Despite this, little previous research has examined whether topiramate attenuates the respective associations of affect and craving with substance use.